Compare Incyte Corporation (INCY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Norfolk Southern Corporation — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Norfolk Southern Corporation trades at $335.84 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 3.1× Incyte Corporation's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NSC | |
|---|---|---|
Market Cap | $24.54B | $75.15B |
Sector | Health | Technology |
52-Week High | $129.93 | $350.66 |
52-Week Low | $81.61 | $272.35 |
Enterprise Value | $20.04B | $90.70B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Norfolk Southern (NSC) trades at $335.41, up 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $369.67. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.52 exceeding expectations, driven by record revenue and volume growth. A pending merger with Union Pacific and a recent dividend declaration highlight ongoing corporate activity.
The outlook is positive, supported by strong operational performance and favorable industry trends, though risks include integration challenges from the merger, premium valuation metrics, and potential economic headwinds affecting freight demand. Investor sentiment is mixed, with analysts predominantly holding a neutral to bullish stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
